fda warning bpc-157 human use not approved panel backs compounded BPC-157, KPV peptides in win for RFK Jr FDA panel narrowly backs unapproved

For better regenerative effects in a shorter period of time, therapy with the BPC-157 peptide is used

Studies in mice demonstrated that a short course of MOTS-c treatment completely reversed age-related insulin resistance in old muscles after one week of MOTS-c administration, older mices muscles responded to insulin as effectively as those of much younger mice

The FDA and the EMA have stated that after review of published and unpublished reports, the current data do not support an increased risk of pancreatitis and pancreatic cancer in patients receiving incretin mimetics

When injections are the right choice When blood tests or clinical context indicate deficiency or malabsorption, intramuscular B12 is an appropriate and often necessary treatment